Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00876408 · ClinicalTrials.gov registry record

Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary Cancer

A clinical trial, sponsored by SCRI Development Innovations.

Completed
Registry status
30
Enrollment target

NCT00876408: Completed study, sponsored by SCRI Development Innovations.

NCT00876408 is a clinical trial that has completed, run by SCRI Development Innovations. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00876408 has completed, sponsored by SCRI Development Innovations.

COMPLETED
Registry status
30 participants
Enrollment target

Study Summary

This will be a retrospective review of 30 patients with unknown primary cancer who have had commercially available RT-PCR assays performed on biopsied tumors, in order to determine if the assay results are consistent with clinical features and useful for planning initial therapy or changing therapy.

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2009-05
Est. Completion 2010-11
SCRI Development Innovations

146 total trials

What the finished NCT00876408 record still lists

NCT00876408 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT00876408 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00876408 about?

NCT00876408 is a clinical study titled "Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary Cancer". This will be a retrospective review of 30 patients with unknown primary cancer who have had commercially available RT-PCR assays performed on biopsied tumors, in order to determine if the assay results are consistent with clinical features and useful for planning initial therapy or changing therapy.

What is the current status of trial NCT00876408?

This trial is currently completed. The enrollment target is 30 participants. The study started on 2009-05. Estimated completion is 2010-11.

Who is sponsoring clinical trial NCT00876408?

This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00876408, the US trial registry maintained by the National Library of Medicine. NCT00876408 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.